Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy
  • CME

Credits Available
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Pharmacists: 1.75 contact hours (0.175 CEUs)
Released: March 23, 2022 Expiration: March 22, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.
Keith S. Kaye, MD, MPH
Program Director
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Jason Pogue Headshot
Jason M. Pogue, PharmD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Understand rapid detection strategies for HABP/VABP considering the burden of disease caused by multidrug-resistant Gram-negative infections and molecular epidemiology
  • Apply appropriate use of new antimicrobial agents and strategies for empiric and targeted therapy in multidrug-resistant, extensively drug–resistant, and difficult-to-treat–resistant Gram-negative HABP and VABP
  • Develop effective strategies to minimize time to effective therapy while incorporating antimicrobial stewardship principle

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH, has disclosed that he has received consulting fees from Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx, Contrafect, Cubist, Entasis, Integrated Operations, Melinta, Merck, Nabriva, NS Nanotech, Pratek, QPex, Shionogi, SPERO, Utility Therapeutics, VenatoRX, and Xellia.

Faculty

Lilian Abbo, MD, FIDSA

Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Lilian Abbo, MD, FIDSA, has disclosed that she has received consulting fees from Ferring.
Jason M. Pogue, PharmD

Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Jason M. Pogue, PharmD, has disclosed that he has received consulting fees from Entasis, GlaxoSmithKline, Merck, QPex, Shionogi, Spero, Utility.

Staff

Jessica Adams, PharmD, BCPS, AAHIVP

Scientific Director

Jessica Adams, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kara Nyberg, PhD

Editorial Contributor

Kara Nyberg, PhD, has no relevant conflicts of interest to report.
Leslie Burgess
Leslie Burgess, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with HABP and VABP.

Goal

The goal of this activity is to improve the knowledge and competence of learners regarding clinical role of new antimicrobial agents in the management of HABP/VABP.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-087-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 23, 2022, through March 22, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Antimicrobial Resistance in HABP/VABP
  • CME

Loading...
Hear expert insights on key concepts in HABP/VABP and Gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Keith S. Kaye, MD, MPH
Program Director
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Jason Pogue Headshot
Jason M. Pogue, PharmD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Pharmacists: 1.75 contact hours (0.175 CEUs)
Released: March 23, 2022 Expiration: March 22, 2023

This program is divided into several short segments that you can access using the Video Chapters menu.

Related Content

Expert faculty discuss ways to improve the empiric treatment of HABP/VABP in the ICU in this commentary from Clinical Care Options (CCO)

person default Marion Elligsen, BScPhm, MSc, RPh, ACPR Keith S. Kaye, MD, MPH Andrew Shorr, MD, MPH, MBA Released: November 18, 2022

Learn from experts about strategies to improve timely, effective antibiotic therapy in patients with HABP/VABP at risk for multidrug resistance, from Clinical Care Options (CCO)

Clinical Care Options (CCO) presents expert faculty discussing RSV in certain adult populations and the development of RSV vaccines

John J. Russell, MD, FAAFP
Program Director
Laura Hurley, MD, MPH Pamela Rockwell, DO, FAAFP
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Released: October 28, 2022 Expired: October 27, 2023

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings